×
About 480 results

ALLMedicine™ POEMS Syndrome Center

Research & Reviews  183 results

A case of POEMS syndrome with severe kidney damage: lessons for the clinical nephrologist.
https://doi.org/10.1007/s40620-022-01379-w 10.1002/ajh.25495 10.6004/jnccn.2022.0002 10.1182/blood-2016-10-746933 10.1002/art.1780290212 10.1093/ndt/14.10.2370 10.1093/ndt/gfw165.07 10.1038/ki.2011.399
Journal of Nephrology; Rekhtina I, Stolyarevich E et. al.

Jun 24th, 2022 - A case of POEMS syndrome with severe kidney damage: lessons for the clinical nephrologist.|2022|Rekhtina I,Stolyarevich E,Zakharova E,Khyshova V,Mendeleeva L,|

Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comp...
https://doi.org/10.1182/bloodadvances.2022007218
Blood Advances; Kansagra A, Dispenzieri A et. al.

May 5th, 2022 - Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.|2022|Kansagra A,Dispenzieri A,Fraser R,Estrada-Merly N,Sidana S,|

POEMS Syndrome: Skin Lesions Bringing the Jigsaw Puzzle Together.
https://www.ncbi.nlm.nih.gov/pubmed/35435828
Skinmed Chhabra N, Sharma H et. al.

Apr 19th, 2022 - A 47-year-old man presented to the outpatient department with multiple asymptomatic, erythematous and violaceous, soft, dome-shaped papulonodular lesions that had been present for 3 years. The lesions were vascular and were about 1 cm in diameter....

Vitamin B6 deficiency as a cause of polyneuropathy in POEMS syndrome: rapid recovery wi...
https://doi.org/10.1080/16078454.2022.2060456
Hematology (Amsterdam, Netherlands); Yasuda H, Furukawa Y et. al.

Apr 13th, 2022 - The etiology of POEMS syndrome and its associated polyneuropathy have not been fully elucidated. The clinical picture of POEMS-associated polyneuropathy and nutritional polyneuropathy due to vitamin B6 (VB6) deficiency are strikingly similar, both...

Cutaneous manifestations of monoclonal gammopathy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001632
Blood Cancer Journal; Claveau JS, Wetter DA et. al.

Apr 13th, 2022 - Monoclonal gammopathy associated with dermatological manifestations are a well-recognized complication. These skin disorders can be associated with infiltration and proliferation of a malignant plasma cells or by a deposition of the monoclonal imm...

see more →

Clinicaltrials.gov  3 results

A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
https://clinicaltrials.gov/ct2/show/NCT05263817

Mar 3rd, 2022 - POEMS syndrome, amyloidosis, autoimmune hemolytic anemia, vasculitis and other diseases may only show local pathological damage or systemic lesions. If they are not diagnosed and treated in time or poorly controlled, they will progress as the cour...

POEMS Syndrome Treatment With Lenalidomide
https://clinicaltrials.gov/ct2/show/NCT01639898

Jul 5th, 2019 - The investigators propose to simultaneously set up two Phase II therapeutic trials: Trial "2 cycles" and trial "9 cycles" (Fleming plan in one stage). This will mean prospective multicentre studies, around a treatment with the lenalidomide-dexamet...

Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome
https://clinicaltrials.gov/ct2/show/NCT01816620

Apr 25th, 2017 - The investigators propose to use the adverse effects as well as the need for dose reduction as a criterion to judge tolerability of treatment. The primary endpoint would be hematological response rate according to international myeloma working gro...

see more →

News  6 results

FDA Grants Orphan Drug Designation to CFT7455 for Multiple Myeloma
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-cft7455-for-multiple-myeloma

Aug 17th, 2021 - The FDA has granted an orphan drug designation to CFT7455, a MonoDAC degrader targeting IKZF1/3, for use as a potential therapeutic option in patients with multiple myeloma, according to an announcement from C4 Therapeutics, Inc.1 We are pleased ...

Ixazomib Frontline Triplet Misses PFS Endpoint in Transplant-Ineligible Myeloma
https://www.onclive.com/view/ixazomib-frontline-triplet-misses-pfs-endpoint-in-transplantineligible-myeloma

Dec 4th, 2020 - Christopher Arendt The triplet therapy of ixazomib (Ninlaro), lenalidomide (Revlimid), and dexamethasone showed an improvement in progression-free survival (PFS), but it was not statistically significant, compared with lenalidomide/dexamethasone ...

Management of Plasma Cell Disorders
https://www.mdedge.com/hematology-oncology/article/146012/lymphoma-plasma-cell-disorders/management-plasma-cell-disorders
Brendan M. Weiss, MD

Jan 1st, 2015 - The plasma cell disorders are a spectrum of conditions that include asymptomatic precursor conditions—monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)—as well as symptomatic multiple myeloma (MM) and.

POEMS syndrome: a significant clinical response to lenalidomide
https://www.mdedge.com/hematology-oncology/article/58441/leukemia-myelodysplasia-transplantation/poems-syndrome-significant
Sumera Salim et al

Feb 1st, 2013 - POEMS syndrome is a rare paraneoplastic syndrome whose cause is unknown. In this case of POEMS syndrome, the patient showed significant clinical improvement after treatment with lenalidomide.

Spontaneous Recovery of Adrenal Insufficiency in POEMS Syndrome
https://www.medscape.com/viewarticle/586058

Jan 22nd, 2009 - Abstract POEMS syndrome is a rare multisystem disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. We report the first case of spontaneous recovery of adrenal insufficiency in a patient w...

see more →